News Vertex Pharmaceuticals Incorporated

Stocks

VRTX

US92532F1003

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:49:35 2026-06-30 EDT			5-day change	1st Jan Change
497.74 ^USD	-0.38%		+6.23%	+9.76%

06-29	Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) added to Russell 1000 Value Benchmark	CI
06-28	Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 3000E Growth Benchmark	CI

All News

Mentions Relevance

06-29	Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) added to Russell 1000 Value Benchmark	CI
06-28	Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 3000E Growth Benchmark	CI
06-28	Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 1000 Growth Benchmark	CI
06-28	Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 1000 Growth-Defensive Index	CI
06-28	Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) added to Russell 1000 Value-Defensive Index	CI
06-28	Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) added to Russell Top 200 Value Benchmark	CI
06-28	Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell Top 200 Growth Benchmark	CI
06-28	Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 3000 Growth Benchmark	CI
06-17	Vertex Pharmaceuticals Insider Sold Shares Worth $1,827,900, According to a Recent SEC Filing	MT
06-11	Vertex's Late-Stage Clinical Data of Casgevy Deliver Crisis-Free, Transfusion-Free Results in Kids With Blood Disorders	MT
06-11	Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions	BU
06-11	Vertex Pharmaceuticals Incorporated Presents New Data on Casgevy and Announces Additional Global Regulatory Submissions	CI
06-10	Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 11:20 AM
06-09	Vertex Pharmaceuticals Insider Sold Shares Worth $785,250, According to a Recent SEC Filing	MT
06-05	Vertex Pharmaceuticals Incorporated Presents New Data On ALYFTREK And TRIKAFTA At European Cystic Fibrosis Conference	CI
06-05	Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference	BU
06-03	Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10	BU
06-02	Vertex Pharmaceuticals Insider Sold Shares Worth $888,300, According to a Recent SEC Filing	MT
06-01	Vertex announces US FDA acceptance of biologics license application for accelerated approval of povetacicept in IgA nephropathy	RE
06-01	Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy	BU
06-01	Vertex Pharmaceuticals Incorporated Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy	CI
05-29	Vertex Pharmaceuticals Incorporated Presents at Bernstein 42nd Annual Strategic Decisions Conference, May-29-2026 09:00 AM
05-21	Vertex Pharmaceuticals Says New Pain Management Drug Is Under Review at Health Canada	DJ
05-21	Vertex Says Health Canada Accepts Suzetrigine Application for Review	MT
05-21	Vertex Pharmaceuticals Announces New Drug Submission for Suzetrigine Accepted for Review by Health Canada	CI